It’s only fair to share… Crelosidenib CAS 2230263-60-0 7-{[(1S)-1-(4-{(1S)-1-[4-(prop-2-enoyl)piperazin-1-yl]-2-cyclopropylethyl}phenyl)ethyl]amino}-1-ethyl-1,4-dihydro-2Hpyrimido[4,5-d][1,3]oxazin-2-oneisocitrate dehydrogenase 1 (IDH1) inhibitor, antineoplastic MF C28H36N6O3 MW 504.6 g/mol Crelosidenib is an investigational new drug that is being evaluated for the treatment of cancer. It acts as a selective inhibitor of isocitrate dehydrogenase 1 (IDH1), an enzyme that plays a crucial role in cellular metabolism and is frequently mutated in various …
Category «Uncategorized»
Copper (64Cu) adarulatide tetraxetan
It’s only fair to share… Copper (64Cu) adarulatide tetraxetan Adarulatide tetraxetan copper Cu-64 CAS 2841388-40-5 MF C76H10764CuN17O22, MF1,674.7 Cuprate(3-)-64Cu, [N-[2-[4,10-bis[(carboxy-κO)methyl]-7-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl-κN1,κN4,κN7,κN10 ]acetyl]-L-α-aspartyl-3-cyclohexyl-L-alanyl-L-phenylalanyl-D-seryl-D-arginyl-L-tyrosyl-L-leucyl-L-tryptophanyl-L-serinato(5-)]-, hydrogen (1:3) N-({4,10-bis[(carboxylato-κO)methyl]-7- (carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-ylκ4 N1 ,N4 ,N7 ,N10}acetyl)-L-α-aspartyl-3-cyclohexyl-Lalanyl-L-phenylalanyl-D-seryl-D-arginyl-L-tyrosyl-L-leucylL-tryptophyl-L-serinecopper 2-[4-[2-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]-7-(carboxylatomethyl)-10-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;copper-64(2+)diagnostic imaging agent, QM8HMM6RJP AS ON JUNE2025 4.45 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT join me on Linkedin Anthony Melvin Crasto Ph.D – India | LinkedIn join …
Claziprotamide
It’s only fair to share… Claziprotamide CAS 2361124-03-8, BBP 671 MF C19H20ClFN4O MW374.8 g/mol 1-[4-(6-chloropyridazin-3-yl)piperazin-1-yl]-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one 1-[4-(6-chloropyridazin-3-yl)piperazin-1-yl]-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-onepantothenate kinases 1 and 3 (PanK1 and PanK3) positive allosteric modulator Claziprotamide is an investigational new drug that is being evaluated for the treatment of rare metabolic disorders such as pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA). It acts as a positive allosteric modulator …
Camibirstat
It’s only fair to share… Camibirstat CAS 2671128-05-3 N-{(2S)-1-[(4-{6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-2-yl}-1,3-thiazol-2-yl)amino]-3-methoxy-1-oxopropan-2-yl}-1-(methanesulfonyl)-1H-pyrrole-3-carboxamideATPase inhibitor, antineoplastic MW C24H30N6O6S2 MF 562.7 g/mol Camibirstat is an investigational new drug that is being evaluated for the treatment of cancer. It is a small molecule that acts as a selective inhibitor of SMARCA2 and SMARCA4, which are key components of the SWI/SNF chromatin remodeling complex.[1] It is being developed by Foghorn Therapeutics.[2] Camibirstat …
Brimarafenib
It’s only fair to share… Brimarafenib CAS 1643326-82-2 MF C24H17F3N4O4 MW482.4 g/mol N-{(1S,1aS,6bS)-5-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl}-N′-(2,4,5-trifluorophenyl)urearapidly accelerated fibrosarcoma (Raf) kinase inhibitor, Antineoplastic, MapKure, LLC, SpringWorks Therapeutics, BeiGene, BGB-3245, BGB 3245, GXS33OY2CB Brimarafenib is an investigational new drug that is being evaluated for the treatment of cancer. It targets the proto-oncogene BRAF with activating mutations BRAF mutations (such as V600E), non-V600 BRAF mutations, and RAF fusions.[1][2] …
Brezivaptan
It’s only fair to share… Brezivaptan CAS 1370444-22-6 ANC-501, THY-1773, TS-121, 575OB1CKN0 MF C25H30ClN5O3 MW 484.0 g/mol 2-[3-(3-chlorophenyl)-1-{4-[2-(morpholin-4-yl)ethyl]phenyl}-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]-N-(propan-2-yl)acetamide 2-[3-(3-chlorophenyl)-1-[4-(2-morpholin-4-ylethyl)phenyl]-5-oxo-1,2,4-triazol-4-yl]-N-propan-2-ylacetamidevasopressin receptor antagonist Brezivaptan[1] (developmental code names ANC-501, THY-1773, TS-121) is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder.[2][3][4] As of November 2022, it is in phase II clinical trials for this indication.[2][3][5] ANC-501 is under investigation in clinical trial NCT05439603 (ANC-501 in the Treatment …
Atumelnant
It’s only fair to share… Atumelnant CAS 2392970-97-5 MF C33H42F3N5O3 MW 613.7 g/mol CRN04894, NR57FH6U1N CRINETICS PHARMA, Orphan Drug Status, Congenital adrenal hyperplasia N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-ethoxyphenyl)-3-[(2R)-2-ethyl-4-[1-(trifluoromethyl)cyclobutanecarbonyl]piperazin-1-yl]pyridine-2-carboxamide N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-ethoxyphenyl)-3-{(2R)-2-ethyl-4-[1-(trifluoromethyl) cyclobutane-1-carbonyl]piperazin-1-yl}pyridine-2-carboxamideAdrenocorticotropic hormone receptor antagonist Atumelnant (INNTooltip International Nonproprietary Name; developmental code name CRN04894) is an investigational new drug developed by Crinetics Pharmaceuticals for the treatment of adrenocorticotropic hormone (ACTH)-dependent endocrine disorders.[1] It is a selective antagonist of the melanocortin type 2 receptor (MC2R), also …
Ateganosine
It’s only fair to share… Ateganosine CAS 789-61-7 MF C10H13N5O3S MW 283.31 g/mol 2′-deoxy-6-thioguanosinenucleoside analogue, antineoplastic Ateganosine is a telomerase inhibitor[1] and apoptosis inducer currently under investigation for the treatment of various cancers, including non-small cell lung cancer (NSCLC).[2] Beta-Thioguanine Deoxyriboside is a thiopurine nucleoside derivative with antineoplastic activity. After conversion to the triphosphate, beta-thioguanine deoxyriboside is incorporated into DNA, resulting in inhibition of DNA replication. This …
Bimokalner
It’s only fair to share… Bimokalner CAS 2243284-19-5 MF C15H18F5NOS MW 355.4 g/mol (1S,2S,4R)-N-{[3-(pentafluoro-λ6sulfanyl)phenyl]methyl} bicyclo[2.2.1]heptane-2-carboxamidevoltage-gated potassium channel (Kv7.4) agonist Bimokalner is an investigational new drug under evaluation for preventing and treating hearing loss caused by cisplatin treatment. It is a voltage-gated potassium channel agonist targeting Kv7.4 and is being developed by Acousia Therapeutics GmbH.[1][2] PAT Compounds useful as potassium channel openers, Publication Number: US-11884642-B2, Priority Date: 2017-02-28, Grant Date: 2024-01-30 …
Asengeprast
It’s only fair to share… Asengeprast CAS 1001288-58-9 FT011, FT 011, orphan drug status, systemic sclerosis, SHP-627, SHP 627, Fast Track 2-[[(E)-3-(3-methoxy-4-prop-2-ynoxyphenyl)prop-2-enoyl]amino]benzoic acid 2-[(2E)-3-{3-methoxy-4-[(prop-2-yn-1-yl)oxy]phenyl}prop-2-enamido]benzoic acid G protein-coupled receptor 68 (GPR68) antagonist,anti-inflammatory MF C20H17NO5 MW 351.4 g/mol. C6V7ZU2NPR Asengeprast (development code FT011) is an experimental scleroderma drug candidate.[1] It is a small molecule inhibitor of the G-protein coupled receptor GPR68 with antifibrotic activity.[2] It is …